Foster & Motley Inc. Sells 22,368 Shares of Pfizer Inc. (NYSE:PFE)

Foster & Motley Inc. lessened its position in Pfizer Inc. (NYSE:PFE) by 15.4% in the 4th quarter, Holdings Channel reports. The firm owned 122,933 shares of the biopharmaceutical company’s stock after selling 22,368 shares during the period. Foster & Motley Inc.’s holdings in Pfizer were worth $3,261,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Allen Capital Group LLC raised its stake in Pfizer by 10.2% during the 4th quarter. Allen Capital Group LLC now owns 125,582 shares of the biopharmaceutical company’s stock worth $3,332,000 after buying an additional 11,661 shares during the period. Strategic Blueprint LLC raised its position in shares of Pfizer by 2.0% during the fourth quarter. Strategic Blueprint LLC now owns 47,169 shares of the biopharmaceutical company’s stock worth $1,251,000 after purchasing an additional 942 shares during the period. Hantz Financial Services Inc. lifted its holdings in shares of Pfizer by 34.5% during the 4th quarter. Hantz Financial Services Inc. now owns 514,184 shares of the biopharmaceutical company’s stock valued at $13,641,000 after purchasing an additional 131,760 shares in the last quarter. Foster Victor Wealth Advisors LLC grew its position in shares of Pfizer by 24.9% in the 4th quarter. Foster Victor Wealth Advisors LLC now owns 564,035 shares of the biopharmaceutical company’s stock valued at $14,834,000 after purchasing an additional 112,616 shares during the period. Finally, Robeco Institutional Asset Management B.V. increased its stake in Pfizer by 41.8% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 6,377,817 shares of the biopharmaceutical company’s stock worth $169,203,000 after purchasing an additional 1,879,504 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on PFE. Citigroup reduced their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Bank of America reissued a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Price Performance

NYSE:PFE opened at $26.65 on Thursday. The stock has a market capitalization of $151.00 billion, a PE ratio of 36.01, a P/E/G ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The firm has a fifty day simple moving average of $26.18 and a 200 day simple moving average of $27.91. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company’s quarterly revenue was up 31.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.17) EPS. On average, research analysts expect that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.46%. The ex-dividend date of this dividend is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.